Addus HomeCare (ADUS)
(Delayed Data from NSDQ)
$127.58 USD
-1.50 (-1.16%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $127.69 +0.11 (0.09%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$127.58 USD
-1.50 (-1.16%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $127.69 +0.11 (0.09%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
ADUS vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
3 Reasons Growth Investors Will Love Addus HomeCare (ADUS)
by Zacks Equity Research
Addus HomeCare (ADUS) could produce exceptional returns because of its solid growth attributes.
ADUS or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
Is Addus HomeCare (ADUS) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Addus HomeCare (ADUS) could produce exceptional returns because of its solid growth attributes.
Top Ranked Momentum Stocks to Buy for January 21st
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 21st.
What Makes Addus HomeCare (ADUS) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Addus HomeCare (ADUS) have what it takes to be a top stock pick for momentum investors? Let's find out.
DGX or ADUS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DGX vs. ADUS: Which Stock Is the Better Value Option?
3 Reasons Why Addus HomeCare (ADUS) Is a Great Growth Stock
by Zacks Equity Research
Addus HomeCare (ADUS) possesses solid growth attributes, which could help it handily outperform the market.
Addus HomeCare (ADUS) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 6.90% and 5.37%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: NRG, AquaVenture, Addus, Amedisys and Bluerock Residential
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NRG, AquaVenture, Addus, Amedisys and Bluerock Residential
5 Top Stocks to Gain From Fed's Stable Monetary Stance
by Nalak Das
Fed was compelled to reduce it in three consecutive and equal tranches of 25 basis points to sustain the expansion of the U.S. economy.
Addus HomeCare (ADUS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Looking for a Growth Stock? 3 Reasons Why Addus HomeCare (ADUS) is a Solid Choice
by Zacks Equity Research
Addus HomeCare (ADUS) possesses solid growth attributes, which could help it handily outperform the market.
What's in Store for Thermo Fisher (TMO) in Q3 Earnings?
by Zacks Equity Research
Developments in business segments are likely to have aided Thermo Fisher (TMO) in the third quarter.
Can Sequencing Products Drive Illumina's (ILMN) Q3 Earnings?
by Zacks Equity Research
Illumina (ILMN) is taking a cautious approach after a disappointing second quarter.
Why the Earnings Surprise Streak Could Continue for Addus HomeCare (ADUS)
by Zacks Equity Research
Addus HomeCare (ADUS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Reasons Why Addus HomeCare (ADUS) Is a Great Growth Stock
by Zacks Equity Research
Addus HomeCare (ADUS) could produce exceptional returns because of its solid growth attributes.
DGX vs. ADUS: Which Stock Is the Better Value Option?
by Zacks Equity Research
DGX vs. ADUS: Which Stock Is the Better Value Option?
Addus HomeCare (ADUS) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 3.70% and 2.07%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Addus HomeCare (ADUS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Ranked Momentum Stocks to Buy for July 16th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 16th.
Top Ranked Momentum Stocks to Buy for July 15th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 15th.
Addus HomeCare (ADUS) Is Up 0.43% in One Week: What You Should Know
by Zacks Equity Research
Does Addus HomeCare (ADUS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Top Ranked Momentum Stocks to Buy for July 2nd
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 2nd.
Addus HomeCare (ADUS) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Addus HomeCare (ADUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).